Crestwood Advisors Group LLC Has $55.72 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Crestwood Advisors Group LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 96,158 shares of the medical research company’s stock after selling 3,635 shares during the quarter. Crestwood Advisors Group LLC’s holdings in Thermo Fisher Scientific were worth $55,719,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Beacon Financial Strategies CORP acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at $29,000. Olistico Wealth LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at $29,000. JPL Wealth Management LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $28,000. Cloud Capital Management LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $31,000. Finally, Thurston Springer Miller Herd & Titak Inc. lifted its holdings in Thermo Fisher Scientific by 195.7% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 68 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 45 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 5,800 shares of company stock worth $2,963,544 in the last 90 days. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Up 0.1%

Shares of NYSE TMO opened at $473.58 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The stock has a market capitalization of $175.99 billion, a P/E ratio of 26.04, a PEG ratio of 2.09 and a beta of 0.88. The stock’s fifty day moving average is $493.53 and its 200 day moving average is $546.70.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same quarter last year, the business earned $5.15 earnings per share. Thermo Fisher Scientific’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were given a $0.47 dividend. The ex-dividend date was Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Analysts Set New Price Targets

TMO has been the subject of a number of research reports. Jefferies Financial Group raised Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. TD Cowen dropped their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a report on Friday, January 30th. Barclays dropped their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. UBS Group reissued a “neutral” rating and set a $615.00 target price on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Finally, Stifel Nicolaus dropped their target price on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a report on Friday, April 24th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $623.05.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.